Effects of Hyperbaric Oxygen Therapy on Mitochondrial Respiration and Physical Performance in Middle-Aged Athletes: A Blinded, Randomized Controlled Trial.
Effects of Hyperbaric Oxygen Therapy on Mitochondrial Respiration and Physical Performance in Middle-Aged Athletes: A Blinded, Randomized Controlled Trial.
复制标题
DOI：
10.1186/s40798-021-00403-w
复制
发表时间：
2022-02-08
期刊：
影响因子：
--
通讯作者：
Efrati S
中科院分区：
文献类型：
--
作者：
Hadanny A;Hachmo Y;Rozali D;Catalogna M;Yaakobi E;Sova M;Gattegno H;Abu Hamed R;Lang E;Polak N;Friedman M;Finci S;Zemel Y;Bechor Y;Gal N;Efrati S
高压氧治疗（HBOT）已被用于提高耐力表现，但尚未在安慰剂对照临床试验中进行评估。本研究旨在评估间歇性HBOT方案对中年运动员最大体能和线粒体功能的影响。在2018年至2020年期间，对37名健康中年（40-50岁）大师级运动员进行了双盲、随机、安慰剂对照研究。受试者暴露于40次重复的HBOT（两个绝对大气压（ATA），呼吸100%氧气1小时）或SHAM（1.02ATA，呼吸空气1小时）。在37名运动员中，16名HBOT和15名SHAM分配的运动员被纳入最终分析。HBOT后，与SHAM组相比，最大耗氧量（VO 2 Max）（p = 0.010，效应量（es）= 0.989）和无氧阈值下测量的耗氧量（VO 2AT）（es = 0.837）显著增加。在HBOT之后，与SHAM阶段相比，最大氧磷酸化能力（es = 1.085，p = 0.04）、最大解偶联能力（es = 0.956，p = 0.02）和线粒体质量标志物MTG（p = 0.0002）均显著增加。HBOT提高了健康中年运动员的身体表现，包括VO 2 max，功率和VO 2AT。其机制可能与线粒体呼吸的显著改善和线粒体质量的增加有关。试用注册ClinicalTrials.gov标识符：https://clinicaltrials.gov/ct2/show/NCT03524989（2018年5月15日）。
Hyperbaric oxygen therapy (HBOT) has been used to increase endurance performance but has yet to be evaluated in placebo-controlled clinical trials. The current study aimed to evaluate the effect of an intermittent HBOT protocol on maximal physical performance and mitochondrial function in middle-aged master athletes. A double-blind, randomized, placebo-controlled study on 37 healthy middle-aged (40–50) master athletes was performed between 2018 and 2020. The subjects were exposed to 40 repeated sessions of either HBOT [two absolute atmospheres (ATA), breathing 100% oxygen for 1 h] or SHAM (1.02ATA, breathing air for 1 h). Out of 37 athletes, 16 HBOT and 15 SHAM allocated athletes were included in the final analysis. Following HBOT, there was a significant increase in the maximal oxygen consumption (VO2Max) (p = 0.010, effect size(es) = 0.989) and in the oxygen consumption measured at the anaerobic threshold (VO2AT)(es = 0.837) compared to the SHAM group. Following HBOT, there were significant increases in both maximal oxygen phosphorylation capacity (es = 1.085, p = 0.04), maximal uncoupled capacity (es = 0.956, p = 0.02) and mitochondrial mass marker MTG (p = 0.0002) compared to the SHAM sessions. HBOT enhances physical performance in healthy middle-age master athletes, including VO2max, power and VO2AT. The mechanisms may be related to significant improvements in mitochondrial respiration and increased mitochondrial mass. Trial Registration ClinicalTrials.gov Identifier: https://clinicaltrials.gov/ct2/show/NCT03524989 (May 15, 2018).
登录
查看更多内容
影响因子：
5.5
作者：
De Bels, David;Tillmans, Frauke;Balestra, Costantino
通讯作者：
Balestra, Costantino
影响因子：
3.3
作者：
Cimino, F.;Balestra, C.;Virgili, F.
通讯作者：
Virgili, F.
DOI：
10.1249/mss.0000000000000321
发表时间：
2014-10-01
期刊：
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
影响因子：
--
作者：
Robach, Paul;Bonne, Thomas;Lundby, Carsten
通讯作者：
Lundby, Carsten
影响因子：
2.2
作者：
Burgos C;Henríquez-Olguín C;Andrade DC;Ramírez-Campillo R;Araneda OF;White A;Cerda-Kohler H
通讯作者：
Cerda-Kohler H
影响因子：
5.6
作者：
Fratantonio D;Virgili F;Zucchi A;Lambrechts K;Latronico T;Lafère P;Germonpré P;Balestra C
通讯作者：
Balestra C